Windtree Therapeutics (WINT) said Wednesday it has tapped New Growth Advisors as its strategic adviser to lead a potential transaction process for its cardiovascular portfolio.
New Growth Advisors will help manage the current inbound interest and run an expanded out-licensing process for the portfolio, Windtree said.
The company said it's looking to secure potentially non-dilutive financing through a partnership for istaroxime and the oral SERCA2a activators for all global territories excluding Greater China.
In Greater China, Windtree has a licensing deal for istaroxime, dual mechanism SERCA2a activators and rostafuroxin with Lee's Pharmaceuticals for which it could receive as much as $138 million in potential milestones and low-double-digit royalties.
Windtree said Lee's expects to launch phase 3 in acute heart failure in its licensed territory in H1 2025.
Windtree shares were down 13.5% in recent trading.
Price: 0.47, Change: -0.07, Percent Change: -13.52
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。